HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,895 | +1.9% | 1,567,911 | -3.8% | 0.01% | +12.5% |
| Q2 2023 | $58,792 | -5.7% | 1,629,901 | -0.2% | 0.01% | -11.1% |
| Q1 2023 | $62,372 | -33.1% | 1,633,184 | -0.3% | 0.01% | -40.0% |
| Q4 2022 | $93,199 | -99.9% | 1,637,959 | +1.4% | 0.02% | +50.0% |
| Q3 2022 | $63,859,000 | -7.2% | 1,615,020 | +3.3% | 0.01% | +11.1% |
| Q2 2022 | $68,788,000 | +10.2% | 1,563,357 | -0.1% | 0.01% | +50.0% |
| Q1 2022 | $62,422,000 | -0.1% | 1,565,247 | +0.7% | 0.01% | 0.0% |
| Q4 2021 | $62,508,000 | +1.4% | 1,554,544 | +2.6% | 0.01% | 0.0% |
| Q3 2021 | $61,629,000 | -10.9% | 1,514,968 | -0.5% | 0.01% | 0.0% |
| Q2 2021 | $69,155,000 | +9.6% | 1,522,909 | +0.6% | 0.01% | 0.0% |
| Q1 2021 | $63,081,000 | +18.5% | 1,513,095 | +21.4% | 0.01% | +20.0% |
| Q4 2020 | $53,248,000 | +3101.9% | 1,246,734 | +1870.2% | 0.01% | – |
| Q3 2020 | $1,663,000 | -84.7% | 63,278 | -84.4% | 0.00% | -100.0% |
| Q2 2020 | $10,888,000 | +655.1% | 406,130 | +406.6% | 0.00% | – |
| Q1 2020 | $1,442,000 | +13.5% | 80,175 | +11.9% | 0.00% | – |
| Q4 2019 | $1,270,000 | +24.1% | 71,630 | +8.6% | 0.00% | – |
| Q3 2019 | $1,023,000 | -8.8% | 65,953 | +1.0% | 0.00% | – |
| Q2 2019 | $1,122,000 | +17.6% | 65,290 | +10.1% | 0.00% | – |
| Q1 2019 | $954,000 | +10.8% | 59,285 | +0.7% | 0.00% | – |
| Q4 2018 | $861,000 | -19.2% | 58,885 | +0.4% | 0.00% | – |
| Q3 2018 | $1,066,000 | +6.7% | 58,663 | -1.0% | 0.00% | – |
| Q2 2018 | $999,000 | +11.7% | 59,226 | +29.8% | 0.00% | – |
| Q1 2018 | $894,000 | -2.7% | 45,645 | +0.6% | 0.00% | – |
| Q4 2017 | $919,000 | -3.0% | 45,378 | -16.7% | 0.00% | – |
| Q3 2017 | $947,000 | +66.7% | 54,508 | +23.0% | 0.00% | – |
| Q2 2017 | $568,000 | -1.0% | 44,308 | +0.0% | 0.00% | – |
| Q1 2017 | $574,000 | +14.1% | 44,300 | -13.0% | 0.00% | – |
| Q4 2016 | $503,000 | -32.3% | 50,900 | -17.2% | 0.00% | – |
| Q3 2016 | $743,000 | +71.6% | 61,500 | +22.5% | 0.00% | – |
| Q2 2016 | $433,000 | +8.0% | 50,200 | +18.7% | 0.00% | – |
| Q1 2016 | $401,000 | -45.3% | 42,300 | 0.0% | 0.00% | – |
| Q4 2015 | $733,000 | +27.3% | 42,300 | -1.4% | 0.00% | – |
| Q3 2015 | $576,000 | -34.4% | 42,900 | +10.3% | 0.00% | – |
| Q2 2015 | $878,000 | +114.1% | 38,900 | +35.5% | 0.00% | – |
| Q1 2015 | $410,000 | +43.4% | 28,700 | -3.0% | 0.00% | – |
| Q4 2014 | $286,000 | +6.3% | 29,600 | 0.0% | 0.00% | – |
| Q3 2014 | $269,000 | -7.9% | 29,600 | 0.0% | 0.00% | – |
| Q2 2014 | $292,000 | -62.1% | 29,600 | -51.2% | 0.00% | – |
| Q1 2014 | $771,000 | -63.9% | 60,700 | -57.4% | 0.00% | – |
| Q4 2013 | $2,134,000 | +151.4% | 142,400 | +85.2% | 0.00% | – |
| Q3 2013 | $849,000 | -22.7% | 76,900 | -44.4% | 0.00% | – |
| Q2 2013 | $1,098,000 | – | 138,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |